Market Overview

UPDATE: Jefferies Downgrades Pfizer on Challenges Ahead

Related PFE
Will The New Pfizer Be A Winner? SunTrust Analyst Thinks So, Upgrades Stock
EXCLUSIVE: FBB's Mike Bailey On Pfizer-Allergan Deal, Taxes, Rate Hike And Biotech Picks
Biotechs Weaken, But These Names Have Bullish Charts (Investor's Business Daily)

In a report published Friday, Jefferies analyst Jeffrey Holford downgraded the rating on Pfizer (NYSE: PFE) from Buy to Hold, and lowered the price target from $32.00 to $30.00.

In the report, Jefferies noted, “Rising rate expectations had the expected impact on the sector, which has been driven by income investors over the past two years. Q2'13 earnings look tough in this context and we expect most companies to see some pressure. Novartis, Sanofi, Roche, Abbott, AbbVie and Bayer remain high conviction Buy ideas. We have downgraded Bristol-Myers and Pfizer to Hold in this report as part of our update today.”

Pfizer closed on Thursday at $28.44.

Latest Ratings for PFE

Nov 2015SunTrust Robinson HumphreyUpgradesReduceNeutral
Nov 2015Argus ResearchMaintainsBuy
Oct 2015Cowen & CompanyUpgradesMarket PerformOutperform

View More Analyst Ratings for PFE
View the Latest Analyst Ratings

Posted-In: Jefferies Jeffrey HolfordAnalyst Color Downgrades Analyst Ratings


Related Articles (PFE)

View Comments and Join the Discussion!

Get Benzinga's Newsletters